Long-term survival in patients with recurrent glioblastoma treated with bevacizumab: a multicentric retrospective study
- 19 July 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 144 (2) , 419-426
Abstract
Recurrence of glioblastoma (GB) occurs in most patients after standard concomitant temozolomide-based radiochemotherapy (CTRC). Bevacizumab (BV), an anti-VEGF antibody, has an effect on progression-free survival (PFS) but not on overall survival (OS). However, a small part of the patients experience a survival, longer than expected. This retrospective study aims to characterize long responder (LR) patients treated with BV for a first or second GBM recurrence. Medical records from patients (814) who received BV for a first or second recurrence of primary glioblastoma between September 2010 and September 2015, and initially treated by CTRC were analyzed. Patients, who had at least a stable disease according to RANO criteria at 12 months from the start of BV, were included. Patients who had, a secondary GB, or received BV in neoadjuvant or adjuvant setting were excluded. We focused on 65 LR patients without progression 12 months after the first injection of BV (8%). Median PFS was 21.7 months [95% CI (19.3; 27.2)] and median OS was 31.1 months [95% CI (24.3; 37.5)] from the start of BV. No prognostic factor was associated with OS in multivariate analysis. Karnofsky performance status, neurological status and corticosteroid dose were stable at 12 months. Our results highlight that among patients receiving bevacizumab in first or second recurrence, one patient out of twelve could be classified as LR. A median OS of 31.1 months from the start of BV could be expected in this subpopulation. These findings reinforce the potential benefit of the use of BV in the situation of recurrence. 256 words.Keywords
This publication has 42 references indexed in Scilit:
- Bevacizumab plus Radiotherapy–Temozolomide for Newly Diagnosed GlioblastomaNew England Journal of Medicine, 2014
- Towards optimizing the sequence of bevacizumab and nitrosoureas in recurrent malignant gliomaJournal of Neuro-Oncology, 2014
- Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiationProceedings of the National Academy of Sciences, 2013
- Long-Term Survival in Primary Glioblastoma With Versus Without Isocitrate Dehydrogenase MutationsClinical Cancer Research, 2013
- Recurrent high-grade glioma treated with bevacizumab: prognostic value of MGMT methylation, EGFR status and pretreatment MRI in determining response and survivalJournal of Neuro-Oncology, 2013
- Relation between bevacizumab dose intensity and high-grade glioma survival: a retrospective study in two large cohortsJournal of Neuro-Oncology, 2011
- Randomized Double-Blind Placebo-Controlled Trial of Bevacizumab Therapy for Radiation Necrosis of the Central Nervous SystemInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2011
- Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working GroupJournal of Clinical Oncology, 2010
- Angiogenesis in brain tumoursNature Reviews Neuroscience, 2007
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005